Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514723Aexternal-prioritypatent/GB8514723D0/en
Priority claimed from GB858514725Aexternal-prioritypatent/GB8514725D0/en
Priority claimed from GB858514722Aexternal-prioritypatent/GB8514722D0/en
Priority claimed from GB858514724Aexternal-prioritypatent/GB8514724D0/en
Application filed by Ciba Geigy AGfiledCriticalCiba Geigy AG
Publication of ES8801384A1publicationCriticalpatent/ES8801384A1/en
Publication of ES555863A0publicationCriticalpatent/ES555863A0/en
Hybrid interferon polypeptide (I) has an aminoacid sequence composed of 2-4 sub-sequences corresp. in aminoacid identity and number to sub-sequences of human lymphoblastoid interferons LyIFN-alpha-2 and LyIFN-alpha-3. (I) has the aminoacid sequence of aminoacids 1-150 of -alpha-2, and 151-166 of -alpha-3; aminoacids 1-92 of -alpha-2, 93-150 of -alpha-3 and 151-166 of -alpha-2; or aminoacids 1-60 of alpha-2, 61-92 of -alpha-3, 93-150 of -alpha-2 or -alpha-3 and 151-166 of -alpha-2 or -alpha-3. Also claimed are the monoclonal antibody 144BS and its derivs. and the hybridoma cell line 144BS 22-6-19, number I-424.